Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 3/2016

01-03-2016 | Commentary

Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?

Authors: Livio Garattini, Anna Padula, Milene Rangel Da Costa

Published in: PharmacoEconomics | Issue 3/2016

Login to get access

Excerpt

Diseases caused by Streptococcus pneumonia contribute considerably to morbidity and mortality worldwide [1]. The main types of illness are grouped as bacteremic pneumococcal pneumonia (BPP) and non-bacteremic pneumococcal pneumonia (NBPP),1 the latter causing less serious manifestations [1, 2]. …
Footnotes
1
Other acronyms often used in studies and overlapping with these two groups are, respectively, IPD (invasive pneumococcal disease) and CAP (community acquired pneumonia).
 
2
The search terms used were ‘pneumococcal vaccine’ or ‘pneumococcal conjugated vaccine’ or ‘pneumococcal polysaccharide vaccine’ combined with ‘cost’ or ‘cost-effectiveness’ or ‘economic evaluation’. We retrieved 103 articles: 65 were discarded because they did not include an EE on a pneumococcal vaccine, and were clinical or epidemiological studies (35); reviews, letters or comments (22); or cost or cost-of-illness studies (8). Then, 25 studies did not concern the EU setting and five focused on children or only high-risk groups of adults.
 
Literature
1.
2.
3.
Koskela M, Leinonen M, Häivä VM, et al. First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants. Pediatr Infect Dis. 1986;5(1):45–50.CrossRefPubMed
4.
Smith KJ. Determining the cost–effectiveness of adult pneumococcal vaccination strategies. Expert Rev Pharmacoecon Outcomes Res. 2014;14(1):1–4.CrossRefPubMed
5.
Fedson DS. Preventing non bacteremic pneumococcal pneumonia in older adults. Hum Vaccin Immunother. 2014;10(5):1322–30.CrossRefPubMed
6.
Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348(18):1747–55.CrossRefPubMed
7.
8.
9.
Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41.CrossRefPubMed
10.
Dirmesropian S, Wood JG, MacIntyre CR, et al. A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly. Hum Vaccin Immunother. 2015;11(4):818–25.PubMedCentralCrossRefPubMed
11.
Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–25.CrossRefPubMed
12.
Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis. 2014;58(7):909–17.CrossRefPubMed
13.
van de Vooren K, Duranti S, Curto A, et al. Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies. Pharmacoeconomics. 2014;32(1):29–45.CrossRefPubMed
14.
15.
Jiang Y, Gauthier A, Keeping S, et al. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):913–27.CrossRefPubMed
16.
Liguori G, Parlato A, Zamparelli AS, et al. Adult immunization with 13-valent pneumococcal vaccine in Campania region, South Italy: an economic evaluation. Hum Vaccin Immunother. 2014;10(2):492–7.PubMedCentralCrossRefPubMed
17.
Jiang Y, Gauthier A, Keeping S. A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):901–11.CrossRefPubMed
18.
Boccalini S, Bechini A, Levi M, et al. Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Hum Vaccin Immunother. 2013;9(3):699–706.PubMedCentralCrossRefPubMed
19.
Pradas R, Gil de Miguel A, Álvaro A, et al. Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model. BMC Infect Dis. 2013;13:175.PubMedCentralCrossRefPubMed
20.
Jiang Y, Gauthier A, Annemans L, et al. Cost-effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany. Expert Rev Pharmacoecon Outcomes Res. 2012;12(5):645–60.CrossRefPubMed
21.
Grzesiowski P, Aguiar-Ibáñez R, Kobryń A, et al. Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland. Hum Vaccin Immunother. 2012;8(10):1382–94.PubMedCentralCrossRefPubMed
22.
Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes. A focused review of modelling approaches. Pharmacoeconomics. 2008;26(3):191–215.CrossRefPubMed
23.
Beutels P. Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination. Vaccine. 2004;22(25–26):3312–22.CrossRefPubMed
24.
Garattini L, van de Vooren K, Curto A. Pricing human papilloma virus vaccine: lessons from Italy. Pharmacoeconomics. 2012;30(3):213–7.CrossRefPubMed
Metadata
Title
Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?
Authors
Livio Garattini
Anna Padula
Milene Rangel Da Costa
Publication date
01-03-2016
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 3/2016
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-015-0341-4

Other articles of this Issue 3/2016

PharmacoEconomics 3/2016 Go to the issue

Consensus Statement

Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community

Original Research Article

Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives

Review Article

Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges

Book Review

Zaheer-Ud-Din Babar (ed): Pharmaceutical Prices in the 21st Century

Original Research Article

Are Efficient Designs Used in Discrete Choice Experiments Too Difficult for Some Respondents? A Case Study Eliciting Preferences for End-of-Life Care

Review Article

Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal